Energy Transfer: Be Additive.

January 16th, 2012

 by James D. Hundley, MD

            If you’ve never been a patient with a serious problem yourself, you may not have considered this for awhile.  Having a medical problem not only drags down your body, it drags down your mind, too.  I’m sure someone taught you about it in medical school, but when we get wrapped up in the technical side of our profession, and it’s necessary that we do so, this is a lesson that some seem to forget.

            Do you know people who are “buzz killers”?  Within a few seconds of being in their presence, you feel your emotional energy being drained and you can’t get away from them quickly enough.  In contrast, those who are bright and energetic make you feel good and ready to tackle anything.

            This is true in the doctor-patient relationship, and it’s serious.  I’ve been around doctors who act so down in the dumps that it seems that they are the ones who need help more than their patients.  Maybe they are tired from working so hard or maybe they are internalizing their worry about the patient, but they sure aren’t helping them tackle their problems.  Whatever the case may be, they are sucking needed emotional energy from their patients rather than filling their patients’ tanks with the fuel they need to deal with their problem.

            I’m not suggesting that you not show concern.  To the contrary, I’m suggesting that you not only show concern for and interest in your patients, I’m suggesting that you be truly concerned and show it by transferring some of your own positive energy to your patients.

            You can’t be silly or trivial.  That’s not what I’m suggesting.  It might take a little practice to find your own best way of approaching this and it’s hard to describe, but it’s about being positive and upbeat to the extent possible in any given situation.

            Players play better for certain coaches.  You frequently hear about it.  I’ve seen it with teams that I’ve worked with.  The same players who were losing miraculously start winning.  Surely the reasons for the sudden success are many.  Maybe it’s conditioning or technique.  They’re important.  Without positive energy, however, I don’t think it happens.

            Likewise, when you rod someone’s femur or replace someone’s hip, the technical aspects are critical, but that’s not enough.  You have to take care of the other physical needs as well, and I’m sure you do, but that’s still not enough.  You must also help that patient find the energy to get up and go again.  Equally as important, no matter how tired you are or what else is going on with other patients or in your life, you must dig down and find positive energy to share with your patient.

            Many will dismiss this as insignificant and/or unrealistic.  I have no scientific studies to support it.  On the other hand, I have had many years of interaction with patients and truly believe that patients do better when they want to please their doctors.  It’s like a player wanting to please his coach.  You can’t fall into the trap of thinking it’s about you personally, of course, but if it’s useful to the patient, it’s certainly not harmful.

            Worried that all of your energy will be drained by your patients?  Don’t be.  In fact, the gratification of seeing your patients happily improving or resolutely dealing with serious problems is in itself a source of energy for you.  It’s like heat reflecting off an object and back to you.  Try it.  You either already know that it’s true or you’ll be pleasantly surprised.

Dr. Hundley is a retired orthopaedic surgeon living in Wilmington.  He is the founder and president of OrthopaedicLIST.com a resource website for orthopaedic and other surgeons and related professionals.

Book Review: barebones. A Surgeons’s Tale. by Augusto Sarmiento, MD

December 31st, 2011

 by James D. Hundley, MD 

barebones is the inspirational story of a bright, ambitious young man imbued with an iron will and an unwavering inspiration to benefit society through Medicine in general and Orthopaedic Surgery in specific.  This review is not intended to be comprehensive nor do I expect book reports to become a routine of the OrthopaedicLIST.com blog.  It’s simply that Dr. Sarmiento’s life history and his views are so interesting and compelling that I wish every orthopaedic surgeon and resident in training, indeed every physician in the United States, would read it.  As for immigrant physicians, Dr. Sarmiento’s story could well become their Bibles.

 The story is well written and describes Dr. Sarmiento’s life and his family struggles when he was a young man through his medical training in Colombia to his orthopaedic residency in the U.S. as an immigrant who could barely speak English to his rise to prominence as an innovator, researcher, academician, and chair of three departments of orthopaedic surgery (two in the U.S. and one in Scotland).  Being elected President of the American Academy of Orthopaedic Surgeons, the largest and among the most prestigious of orthopaedic surgeon associations is evidence of the esteem by which he was held by his fellow surgeons.

As a resident in orthopaedic surgery in the late 60’s and early 70’s I well remember his innovative, dynamic treatment of long bone fractures as it rose to prominence.  I was fortunate to have received my training in a conservative program where the closed treatment of fractures was the first consideration and ORIF was simply one of the choices.  Moving from a long-leg cast to a PTB one for tibia fractures was a huge advance for our patients. 

Dr. Sarmiento’s interest and expertise in the treatment of adult hip problems was not as well known, but he contributed significantly to that field as well.

 The most compelling message from the book relates to Dr. Sarmiento’s observations of the changes in focus by some orthopaedic surgeons during his career.  Dr. Sarmiento was steadfast in putting the interests of his patients first and foremost while having to fight bureaucrats in hospitals and academic centers as well as politicians and observing and feeling the effects of powerful, fellow orthopaedic surgeons who put self interest before that of their patients and medical centers.

 He also documents the efforts and effects of the powerful orthopaedic companies whose “good business” practices were not necessarily “good for patient” practices and believes that these companies have almost taken over the postgraduate education of orthopaedic surgeons.  He believes that the spiraling cost of medical care is one of the unfortunate side effects of that particular shift in source and surgeons practice “cosmetic bone surgery”, surgery that is not indicated for human function.

My only criticism of the book is that Dr. Sarmiento tends to paint our profession with a broad brush of negativity and, like most of us, is concerned that our medical profession will not continue to attract the best and brightest to become physicians.  Fortunately, the numbers and academic qualifications for those applying to medical schools have never been higher.  Hopefully those people will also make good doctors, a concern also addressed by Dr. Sarmiento.

I wish that I could require every orthopaedic surgeon, resident and practitioner, to read Dr. Sarmiento’s barebones.  As that is not within my power, I can only hope that this brief review will entice more to do so. 

barebones.  A Surgeon’s Tale

by Augusto Sarmiento, MD

Prometheus Books

59 John Glenn Drive

Amherst, New York 14228-2197

www.prometheusbooks.com

Published 2003

379 pages

Dr. Hundley is a retired orthopaedic surgeon living in Wilmington, NC and president of OrthopaedicLIST.com.

Experiences to Ponder Upon

November 25th, 2011

 by Augusto Sarmiento, MD

 The meaning of certain events in our lives often escapes careful consideration as they appear at first glance to be inconsequential. Much to our regret, when later on we find ourselves reflecting on those episodes, we painfully recognize the blindness that kept us from appreciating their importance.

Because of the rapid and spectacular advances made in Orthopaedics over a relatively short period of time, we have grown accustomed to seeing virtually all changes as natural and acceptable phenomena. This rapid acceptance explains why it is that so many new ideas, techniques or surgical procedures come into the scene where they stay for only a brief time, then to be replaced by new ones also likely to undergo the same fate.  The short life span of some techniques and surgical operations not infrequently results in harm to an unknown number of patients. It is possible that this particular problem will eventually be assuaged through better mechanisms of surveillance before implementation.  

We must be aware that change does have to become thoughtless complacency. There are instances when opposition to change is mandatory since every change is not necessarily beneficial. The history of the world is replete with situations where change was accepted without careful scrutiny leading to disastrous consequences. If one feels that evolving changes are wrong and likely to lead to future problems, there is an obligation to express those feelings in a manner that sometimes even loud protestations against them become a must. I have previously described the time when as a resident I was fired from the job for refusing to follow orders to perform a certain surgical procedure which I felt was inappropriate and likely to be harmful to the patient.  Fortunately, a few weeks later I was called and asked to return to duty.

I have for the past several decades expressed, even in harsh terms, concerns over trends of a metaphysical nature that without solid empirical evidence seem to have found a comfortable niche in the practice of the profession. Some of them relate to the erosion of the moral fabric of the profession, which is likely to have deep, meaningful consequences.   

          Since medical care is a microcosm of the larger society, unhealthy forces that oftentimes dictate the evolution of our society regarding health care issues have found a home in our professional lives. In the world of economics, commerce stands and prospers on the premise that suggests that in order to increase profit everything is O.K. and therefore nothing is morally wrong Gaining greater and greater financial benefits is the name of the game.

          There should be no argument over the reality that the ethos of Orthopaedics today is quite different from the one that governed for many a generation. From being primarily a profession, Orthopaedics is becoming a business to the point that to many practitioners “profit” is its true raison d’etre.

          The relationship between Orthopaedics and Industry has been described as “corrupted” by the Justice Department of the United States, which is currently conducting a formal investigation hoping to correct the myriad of widespread commission of “serious ethical transgressions.” Wondrous kickbacks, perks and dishonest transactions are reported throughout the land, not only in the academic sector but in the large private practice component.

          In trying to define the genesis of the problem one most conclude that a most important unhealthy feature is the imbalanced relationship between Orthopedics and Industry since Industry is in virtual control of the education of the orthopaedist and related research. For all practical purposes, the orthopaedic curriculum at the residency level as well as in the private sector is in Industry’s hands. This fact has not escaped residents whom I suspect are beginning to react to it.

          I witnessed a few weeks ago an episode that in a major way contributed to my displeasure with the trend, while at the same time bringing hope for a better future. I walked into a clinic room where two residents, one a senior one and the other a third-year, were discussing an episode that the junior resident had experienced a few days earlier. An elderly lady, a friend of his family, had fallen and injured her wrist. He took her to a hospital in the neighborhood where she had x-rays of her wrist taken. Indeed, she had sustained a simple fracture of the distal radius, of the type that readily lends itself to nonsurgical treatment and requires nothing more than a cast for a few weeks.  The resident called the hand surgeon to whom he described over the phone the benign nature of the fracture. The expert surgeon immediately responded, “I will have my secretary schedule her for surgery to be performed tomorrow morning.” He had decided on the surgical treatment without even seeing the patient, examining her wrist or reading the films.

Obviously, the reason for this wrong, unprofessional and unethical performance was the product of a deeply ingrained belief that a most important goal in his practice was to make as much money as possible. The financial compensation for his proposed surgical approach was much higher than what he would have received from a simple, uncomplicated, nonsurgical approach. I know that the two residents were well aware that there are many wrist fractures when surgery is the treatment of choice, but others, like the one they were discussing do not fall into that category.

While the conversation was still in progress, a third resident joined the group. He took the floor and discussed the fact that at a certain sports-medicine expert had in his office a standard order that any new patient seeking a consultation had to have an MRI prior to meeting the surgeon. The residents’ comments were an expression of their resentment of the ongoing trends to which they were being exposed every day and the manner in which unprofessional, unethical habits were being instilled in their minds. 

This episode where three residents were expressing concern over the ongoing evolving ethos in the profession was highly rewarding to me. It lead me to believe that there is a hope that the next generation of orthopaedists might continue its revulsion of the ways the profession is being practiced with greater frequency, and will retain that attitude for the rest of their lives. Wondrous, wishful thinking? Perhaps, but I will try to keep alive the dream for as long as I can.

Dr. Sarmiento is the former Professor and Chairman of Orthopaedics at the Universities of Miami and Southern California, and past-president of the American Academy of Orthopaedic Surgeons.  He is a contributor to Implant Identification on OrthopaedicList.com and has guest authored a number of other articles for this blog.

ORTHOPAEDICS AND REHABILITATION

July 24th, 2011

by Augusto Sarmiento, M.D

A close working relationship between Orthopaedics and Physical and Occupational therapy is in the best interest of all parties. Patients benefit immensely from the allied health professionals services they provide to the point that a scenario where they are absent is inconceivable. I state this premise at the outset of this commentary to shed light into remarks I make in subsequent paragraphs, which might be misconstrued as negative to the relationship. I also briefly summarize my personal history as it relates to my involvement with rehabilitation during my long career in orthopaedic surgery in order to emphasize my serious commitment to the cause.

While still a young faculty member in the Division of Orhopaedics at the University of Miami, I began to develop interest in rehabilitation. My interest was triggered by a presentation made by Doctor Howard Rush, the leading rehabilitation authority in the United States in the 1960s. He presented to the audience his experiences with the rehabilitation of spinal cord injury patients. It was an unforgettable event since up to that time I was convinced that people who sustain the devastating injury were condemned to die within a short time from a variety of complications.

I made up my mind that very same evening that a similar program could be developed in Miami. After a four-day visit to the Rusk Institute in New York City and a struggle with the hospital administration, we succeeded in obtaining funds to recruit registered Physical Therapists and to occupy a condemned hospital ward to accommodate patients with paraplegia or quadriplegia. We had succeeded in establishing the first Spinal Cord Injury Center in the city; as a matter of fact in the State of Florida. A few years later an entire building was devoted to Rehabilitation. 1, 2., When in 1970 I was appointed the first chairman of the newly created Department of Orthopaedics, I suggested and got approval from the Dean of the School to name the department “Orthopaedics and Rehabilitation.” It was the first such department in the country. However, by that time I had already realized that the rehabilitation of spinal cord injured patients requires a great deal of objectivity and the realization that functional ambulation for them is still an unrealized dream. 2

Similar type of objectivity is needed in the relationship between orthopaedists and physical and occupational therapists. Much too often orthopaedic surgeons contribute to the cost of care by recommending long periods of therapy for conditions where supervised treatment is not necessary. This pattern is growing at a fast pace. In increasing numbers many patients recovering from minor surgery or mild disabilities seem to have come to the conclusion that supervised and lengthy periods of therapy are essential for their recovery and request them. However, we must be aware that even within this group there are patients who for one reason or another benefit from formal supervised therapy to initiate the rehabilitation process and to continue it for additional time if necessary.

Muscle strengthening exercises is a commonly prescribed modality for a variety of conditions However, if they are initiated during the inflammatory stage, very often the pain is increased and maintained longer than necessary. The resistive exercises should be carried out after the subsidence of acute pain and, in general, when weakness is the real culprit and not the pain.  

Inappropriate actions, no matter who commits them, should be exposed and criticized. In orthopaedics, the abuse of surgery, which is frequently driven by personal greed, the prescription of expensive tests such as MRIs and CT scans when they are not essential for the provision of good care, and the institution of physical and occupational therapy modalities when they are unnecessary, are appropriate representative examples. The growing cost of cost of medical care, a significant issue at this time, must be addressed in earnest since the country is desperately trying to cope with a critical financial situation. It behooves all us, surgeons and therapists, to be part of the solution rather than part of the problem. Medicine should not have profit as its raison d’etre.

Since the cost of health care is reaching unsustainable and unaffordable levels, country-wide draconian measures, such nationalization of Medicine and the Pharmaceutical and Surgical Implant Industry, can become a reality. 3, 4 Accustomed as we are to a capitalistic laisssez-faire and democratic system we dread the possibility of such a scenario becoming a reality.

———————————————————————————

REFERENCES.

1.         Sarmiento, A. and McCollough, N. The Orthopaedist and                 Rehabilitation. Clin. Orthop.& Rel. Res. 41:111-115, 1965.

Sarmiento A. Bare Bones. Prometheus Publishers, 2005.

D. and Wasumma A. Medicine and the Market.  John Hopkins, 2006.

     4.     Relman A. Doctors as the key to Health Care Reform. New England Journal of medicine.  361, 13:12251227. 2009

Dr. Sarmiento is the former Professor and Chairman of Orthopaedics at the Universities of Miami and Southern California, and past-president of the American Academy of Orthopaedic Surgeons.  He is a contributor to Implant Identification on OrthopaedicList.com and has guest authored a number of other articles for this blog.

It’s OK to Do the Right Thing

June 26th, 2011

by James D. Hundley, MD

            As a retired orthopaedic surgeon, I miss the hallway consultations where colleagues discuss cases while trying to determine the best course for our patients.  Fortunately I am still consulted from time to time and get to enjoy sharing ideas and opinions.

            A few weeks ago I was called by a young surgeon who was perplexed by what would be best for his patient, an elderly, emaciated, osteoporotic woman with end-stage Parkinson’s Disease.  She had suffered a displaced, four-part fracture of her proximal humerus from a fall.  He had been taught that these need open reduction and internal fixation (ORIF) if the patient is to regain good function and felt obligated to offer that as a choice.  When so offered, she had stated that she did not want surgery but would think about it.  When he called me, he was dreading that she would call him in the next day or two saying she wished to proceed with ORIF.  How should he respond?

            For me the answer was easy.  Treat her with a sling and swathe until the acute pain had subsided and then begin gentle range of motion exercises.  Sure, she would never regain function anywhere near normal but she could still use her elbow and hand to eat and for other similar activities.  Even better, she could bypass the possibility of anesthetic complications and surgical ones such as infection, blood loss, loss of fixation, nerve injury, and so on.

            Being the one “in the trenches”, however, and having been taught that the proper treatment was operative, the decision-making for him was more stressful.  He felt that the right thing to do was non-surgical, but feared that that would not be acceptable morally and could put him at risk for a lawsuit.  That’s when I reassured him by saying, “It’s OK to do the right thing.”

            I’ve always felt that decision-making is the most difficult part of orthopaedic surgery.  Sure, you must have a significant degree of core knowledge to understand the disorder and have an array of treatments at your disposal.  Probably the biggest decision is whether or not to operate and when if ever to do it.  If you don’t do surgery, how else would you best treat the patient?  If you do surgery, what is the best procedure?  If you run into surprises during surgery, what do you do then?  In every instance, the best decision is what is best for that particular patient at that particular time.  Sometimes, “doing the right thing” requires you to swim against the tide of current opinion and/or what you learned during your training years.  Over time, however, with personal experience and through seeing a variety of perfectly acceptable ways that our colleagues manage similar problems, we can and must learn to trust our judgment as to what is best for our patients.  Thus, no matter which way the fads are pointing at the time, when you include the patient’s wishes and do the right thing, it is always OK.  In fact, it’s more than OK.  It’s what should be done.

Epilogue:  In case you’re wondering, the patient remained steadfast and decided to not have surgery.  Had she requested it, I don’t know what he would have done, but I’ll bet he would have declined to do it.  Thus, although the whole conversation was moot it was interesting and will hopefully help him the next time he is conflicted by what he thinks he should do vs. what he thinks others would have him do.

Dr. Hundley is a retired orthopaedic surgeon with forty years of experience.  He is also a founder and the president of OrthopaedicLIST.com, a free and open-access directory of orthopaedic products and services that was established in 2003 and currently lists over 10,000 products and services for orthopaedic surgeons and related professionals.

Issues to Address

April 14th, 2011

by Augusto Sarmiento, M.D.

The medical profession and the lay community continue to be bombarded on a daily basis with information arising from a myriad of opinions dealing with the escalating costs of care, which according to many, has reached unaffordable and unsustainable levels. Medical care cost has soared to the point where it is responsible for 16% of the national budget expenditures.

The resulting confusion paralyzes progress, while the condition becomes exponentially worse.       For people who like me, possessing only limited understanding of the complexity of the issues involved, all we can do is try to gain additional meaningful knowledge so that when we express individual opinions our voices have a better change of being heard. With that attitude in mind, I discuss my perceptions on two issues where the medical profession can play a major role: rationing of medical care and abuse of services.

The mere mention of rationing provokes an immediate and oftentimes violent reaction from which politicians and extremists readily take advantage. This issue, steeped in cultural and traditional religious reasons, has prevented a serious and candid analysis of its true meaning. Furthermore, it precludes efforts to determine whether or not the time has come for the citizenry of this country to consider if a system with elements of rationing, but without abandoning its foundations, can be found. It is rather sophomoric to negate that several other highly advanced counties around the world have done such a soul searching and adopted health-care delivery mechanisms that ration services but have continued to provide good medical care while lowering its costs. This has been done without compromising basic human values and sensitivities.  In America, the state of Oregon has had in place during the past few years a system with elements of rationing which other states hopefully are carefully studying.

One area where rationing must be carefully and dispassionately addressed is the so-called end of life care. It has been documented that at this time 95% of healthcare dollars are spent in the last 30 days of life. How it is possible is that such an egregious and incomprehensible figure cannot be brought to the center of the political debate rather than deliberately keeping it away from the discussion table?

To look at rationing only as vehicle to reduce health care cost is not appropriate. Objectivity and common sense in related matters are also very important. As physicians we were told from the first days in medical school that uppermost in our professional life we had the responsibility to use all available means to preserve life, never to give up, and adherence to the principle of “Primum non nocere.” However, we much too often lose objectivity and find it difficult to act in a manner that at first glance seems to run contrary to traditional  precepts and values.

A visit to a Surgical Intensive Care Unit is a vivid example of the many times when our commitment to prevent death makes us follow irrational routes. Does it make sense to keep alive for weeks and weeks an octogenarian barely alive, suffering from a long history of debilitating medical conditions, who now suffers from the effects of a stroke? Why is it that these hospital units are always full of patients, many of whom never return home?

The answers given to this reality are not of a universal nature. There are times when the attending physicians sincerely believe that discontinuing the respirator and feeding tubes is not necessarily right since recoveries from the recent event is possible and justify continuing treatment. At other times the treating doctors surrender to pressure from relatives who for reasons dictated by emotion refuse to accept the verdict that life is no longer possible to maintain. Unfortunately, there are other times when keeping such patients under care brings financial benefits to the treating physicians and hospital.

In my case it is difficult to intelligently verify the latter situation because I have never spent time in Intensive Care Units as part of my professional work. I base my suspicion on observations of the manner in which some dishonest surgeons perform major elective surgical procedures, such as total hip or knee replacement, in elderly patients that can be satisfactorily managed symptomatically. Many of these patients die during their hospitalization or shortly afterwards. The greed and avarice of these people result in enriching their pockets.

If a truly confidential polling were to be conducted regarding the need to develop a sensible and humane system to prevent the futility of unrealistic prolongation of life, I suspect the vast majority of people with a modicum of intelligence and education would agree that rationing of some degree would be welcome. Likewise, a comparable means to prevent the performance of unnecessary surgery would be applauded.         

Acceptable systems can be structured, though very difficult to gain wide and rapid acceptance. In the case of the end of life issues it would take a coordinated effort where representatives from various segments of the government, religious and educational organizations, the media, the medical profession and society as whole would get together to as dispassionately as possible to educate each other on the seriousness of the problem at hand and the unintended consequences likely to come from a refusal to address it.

When it comes to the abuse of expensive and unnecessary diagnostic and therapeutic modalities and surgeries, the medical profession has the moral power to play a major role in the resolution of the crisis. It would take, however, a deliberate effort to set aside the fruitless perpetuation of the concept that medicine is no longer a profession but a business to be squeezed to the maximum. Organized medicine would play a most pivotal place by divorcing itself from the control of education, research, and patient care that it selfishly relegated to the pharmaceutical and surgical implant industry. Through meaningful mechanisms to prevent continued tolerance of what the Justice Department’s current investigation of what it calls “egregious ethical transgression” in the relationship between orthopaedics and industry, much could be accomplished. Forbidding individuals with conflicts of interest to hold office in organized administrative and educational organizations would be essential.

Dr. Sarmiento is the former Professor and Chairman of Orthopaedics at the Universities of Miami and Southern California, and past-president of the American Academy of Orthopaedic Surgeons.  He is a contributor to Implant Identification on OrthopaedicList.com and has guest authored a number of other articles for this blog.

The Prayer of a Surgeon Emeritus

March 30th, 2011

by Howard H. Steel, MD

Lord, Thou knowest I am growing older.

Keep me from becoming talkative and possessed with the idea that I must express myself on every subject.

Release me from the craving to straighten out everyone’s affairs.

Keep me from the recital of endless detail.  Give me wings to get to the point.

Seal my lips when I am inclined to tell of my aches and pains.  They are increasing with the years, and my love to speak of them grows sweeter as time goes by.

Teach me the glorious lesson that occasionally I may be wrong.

Make me thoughtful but not nosy, helpful but not bossy.  With my vast store of wisdom and experience, it does seem a pity not to use it all,

but Thou knowest, Lord, that I want a few friends at the end.

 [Published with permission from Dr. Steel.]

Howard Steel, MD is an icon in Orthopaedics and his inspiration goes beyond Orthopaedics.   Clinically he dedicated his career to children at Temple and the Shriners.  Educationally, he taught thousands of residents, medical students and junior faculty about surgery and life.  In 1970, he founded the Eastern Orthopaedic Association and was the Society President for the first two years.  He has hardly missed a meeting since.  Recognizing there is more to life than medicine, Dr. Steel donated funding (30+ years) for a “non-Orthopaedic” lectureship for many of the regional orthopaedic societies, the AOA and other orthopaedic entities.   Howard is funny, fun-loving and bigger than life. 

 
Comments about Dr. Steel by Judith F. Baumhauer, MD MPH, University of Rochester School of Medicine and Dentistry

Thromboprophylaxis in Orthopaedic Surgery

March 5th, 2011

Richard J. Friedman, MD, FRCSC

 Abstract

Venous thromboembolism is a serious complication after total hip or knee surgery and there is a well-established clinical need for thromboprophylaxis. However, in a large number of cases adequate administration of thromboprophylaxis does not seem to occur after total joint arthroplasty. A major challenge in the management of thromboprophylaxis is to balance the benefits of treatment with the risks, including bleeding complications. Another potential barrier to the optimal use of thromboprophylaxis could be the inconvenience of currently available agents. Many surgeons therefore adopt a conservative approach towards thromboprophylaxis. Simplifying therapy with more convenient, efficacious and safe anticoagulants could change attitudes to anticoagulant use, and improve adherence to thromboprophylactic guidelines.

Introduction

Venous thromboembolism (VTE) is a serious complication after major orthopaedic surgery [1]. The rates of venographic deep vein thrombosis (DVT) and proximal DVT 7 to 14 days after major orthopaedic surgery in patients who receive no thromboprophylaxis are approximately 40% to 60% and 10% to 30%, respectively [1]. The manifestation of DVT is, to some extent, a consequence of bone damage during surgery, when procoagulant debris triggers thrombin generation, resulting in hypercoagulability [2]. In addition to hypercoagulability, the other components of Virchow’s triad of venous stasis and endothelial damage are also thought to play a part in thrombosis [3]. Thus, there is a well-established clinical need for thromboprophylaxis after arthroplasty [1].

A major challenge in the management of anticoagulants is to balance the benefits of treatment with the risks, including bleeding complications. Many surgeons appear concerned about postoperative bleeding and tend to adopt a conservative approach towards the relative risks and benefits of thromboprophylaxis [2]. Consequently, although evidence-based guidelines and recommendations advocate the use of anticoagulants after major orthopaedic surgery, thromboprophylaxis is still used suboptimally [4–6]. However, the evidence that careful prophylaxis administered at an appropriate time after surgery causes surgical bleeding is sparse [7]. In this review, current trends in thromboprophylaxis after orthopaedic surgery in the United States (US) are described. Factors limiting appropriate implementation of thromboprophylaxis regimens are also discussed 

Current Standard of Care

Further to the consensus document developed by the National Institute of Health in 1986 [8], there have been a series of American College of Chest Physicians (ACCP) guidelines published on the use of pharmacological agents for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA), last updated in 2008 [1].

In the US, the available options for anticoagulation and thromboprophylaxis after elective THA or TKA are the vitamin K antagonists (VKAs, e.g. warfarin), the low molecular weight heparins [LMWHs]), and fondaparinux (an indirect Factor Xa inhibitor). Each of these options is associated with significant limitations that complicate use in clinical practice. VKAs have been the mainstay of oral anticoagulant therapy for more than 60 years [9]. However, VKAs have unpredictable pharmacokinetics and pharmacodynamics, and significant inter- and intrapatient variability in dose–response relationships. They are associated with multiple drug–drug and food–drug interactions and have a narrow therapeutic window [9]. Regular coagulation monitoring is therefore required to ensure that the international normalized ratio is within the recommended range of 2.0 to 3.0. The heparins are administered subcutaneously, which means patients often require daily appointments or a nurse visit to administer their medication. LMWHs are also associated with the risk of developing heparin-induced thrombocytopenia [10]. Fondaparinux is also administered subcutaneously, and is contraindicated in patients with severe renal impairment and in those that weigh less that 50 kg. In patients over the age of 75 who have undergone THA or TKA, fondaparinux causes an increased risk of bleeding [11].

The timing of initiation of prophylaxis depends upon the type of anticoagulant used. Warfarin therapy is generally initiated prior to surgery because of its delayed onset of action, whereas prophylaxis with LMWH can be started 10–12 hours before or 12–24 hours after surgery. There does not seem to be a clear advantage with either regimen, and both regimens are recommended by the ACCP [1]. Thromboprophylaxis is recommended to continue for at least 10 days after joint replacement surgery, with extended prophylaxis for up to 35 days recommended for those patients undergoing THA surgery and with a suggestion that thromboprophylaxis for up to 35 days could be beneficial for those undergoing TKA [1]. Traditionally, thromboprophylaxis used to continue only until the patient was discharged from hospital [12], despite the fact that this could be a suboptimal duration [13] and the risk of DVT and mortality after discharge is considerable [14, 15]. The median length of stay in US hospitals is now as short as 3 days after THA and 4 days after TKA [16]. A retrospective study of the medical records of 3,778 orthopaedic surgery patients found that 88% were discharged from hospital and prescribed warfarin or acetylsalicylic acid [6].

Suboptimal Utilization of Thromboprophylaxis

Despite the fact that thromboprophylaxis is now recommended for routine use after total joint arthroplasty, it is not always used optimally. Approximately 10% of patients received inadequate in-hospital thromboprophylaxis, and approximately 33% received inadequate post-discharge thromboprophylaxis according to findings from the US Hip and Knee Registry (1996–2001) [17]. An analysis of the data from the multinational Global Orthopaedic Registry (GLORY) to evaluate the compliance of surgeons with the ACCP guidelines for the prevention of VTE showed that only 47% of THA patients and 61% of TKA patients received prophylaxis in accordance with the recommended start time, duration and dose/treatment intensity recommended by the guidelines [16]. Although nearly all patients received prophylaxis on the first day after surgery, more than a quarter did not receive any form of prophylaxis 7 days after surgery [18].

 

Suboptimal thromboprophylaxis decreases patient outcomes, resulting in many patients remaining at unnecessary risk of thrombosis and its complications [4]. The reasons for lack of compliance with the guidelines may be numerous. They include lack of awareness, poor understanding or disagreement with guidelines (either specifically or as a general concept), resistance to changing established practices, and doubt that a new approach will change outcomes. Established surgeons may also be reluctant to use new anticoagulant regimens because of a fear of increased bleeding risk [17]. Attitudes may also limit a physician’s willingness to follow guidelines. An awareness of the guidelines does not necessarily mean physicians have sufficient knowledge to critically evaluate and apply recommendations [4].

Other potential barriers include the mistaken belief that a small asymptomatic DVT is not important because it cannot cause clinically significant pulmonary embolism (PE) [19], which fortunately is only held by a minority [20]. Due to the often clinically silent nature of VTE, and the low incidence of VTE during the short postoperative hospital stay, the chances of a surgeon witnessing a major DVT or an acute PE are rare [4]. In addition, the trend towards earlier hospital discharge means that many symptomatic events occur after that time [21, 22], and patients are often seen by other specialists when referred back to hospital with a venous thromboembolic event; therefore, surgeons are often unaware of the true incidence of VTE in their patients.

Long-term sequelae of VTE are frequent and often disabling [23]. Recurrent VTE can occur after surgery, although the incidence is less than in other patients groups such as those with cancer [24]. Thrombosis damages the deep venous valves resulting in venous reflux and venous hypertension of the lower limbs. This residual venous obstruction and inflammation are thought to be responsible for the development of post-thrombotic syndrome [25, 26]. Chronic thrombotic pulmonary hypertension, which is associated with considerable morbidity and mortality, occurs in approximately 3–4% of patients over 2 years after a symptomatic PE [27].

Economic Impact of Venous Thromboembolism

The acute and chronic phases of VTE related care have substantial economic consequences [28, 29] that can be effectively modeled [30]. A recent study found the total annual healthcare cost for a VTE ranged from $7,594 to $16,644, depending on the type of event and whether it was a primary or secondary diagnosis. The hospital readmission rates for DVT or PE within 12 months were 5.3% for primary and 14.3% for secondary diagnoses [31]. These data indicate that thromboprophylaxis with anticoagulants should not only be beneficial to patients, but could also be cost effective for the healthcare system [32, 33].

Need for More Convenient Anticoagulants

Another potential barrier to the optimal use of thromboprophylaxis could be the inconvenience of currently available agents [34]. Orthopaedic surgeons and their patients would benefit from an oral anticoagulant that could be administered in fixed doses [35].

Simplifying Therapy

Non-compliance can result in a poor quality of life and increased medical expenditures in managed care. In a study of diabetic patients, total medical costs were approximately $4,500 for patients at 80–100% adherence compared with approximately $8,900 for those at 1–19% adherence [36]. A variety of factors affect non-compliance, but simplifying treatment has been shown to improve adherence in asthma patients [37] and cardiovascular patients given single-pill amlodipine/atorvastatin were found to be approximately three times more likely to achieve adherence over 1 year of follow-up than patients given a two-pill regimen [38]. Similarly, simplifying therapy to a once-daily regimen in virologically suppressed HIV-1-infected patients improved adherence and patient satisfaction [39].

Novel Anticoagulants

Anticoagulants in development are targeting different steps in the coagulation pathway to provide simpler alternatives to currently available anticoagulants. Among these new agents are direct thrombin inhibitors and direct Factor Xa inhibitors [40]. The direct thrombin inhibitor dabigatran etexilate appears an attractive alternative to the current standard of care in patients after THA and TKA [41–44]. It has been granted marketing authorization in the European Union and Canada for the prevention of VTE after THA or TKA. The manufacturer’s recommended dose is 220 mg once daily (starting 1–4 hours after surgery with a single 110 mg capsule) for a total of 28–35 days after THA or a total of 10 days after TKA [45]. Direct Factor Xa inhibitors in development include rivaroxaban, apixaban, edoxaban (DU-176b), and YM150, and of these rivaroxaban is in the most advanced stage of development [46]. Rivaroxaban has shown potential as a once-daily, oral anticoagulant that may be administered in fixed doses for the prevention and treatment of thromboembolic disorders following orthopedic surgery [47–52]. Rivaroxaban is approved in more than 90 countries worldwide, including the European Union and Canada, for the prevention of venous thromboembolism after elective hip or knee replacement surgery in adult patients. A dose of 10 mg once daily (with the initial dose 6–10 hours after surgery, provided that hemostasis has been achieved) for 5 weeks after elective hip arthroplasty or 2 weeks after elective knee arthroplasty is recommended by the manufacturer [53].

 

The main difference between direct thrombin inhibitors and direct Factor Xa inhibitors is their mechanism of action. They also differ in their pharmacokinetic and pharmacodynamic profiles, such as metabolism. For example, in the case of dabigatran, more than 80% of the systemically available drug is eliminated by renal excretion [54]. Two-thirds of administered rivaroxaban is metabolized to inactive metabolites (half of this is eliminated via the kidneys and half via the fecal route), and one-third is excreted as unchanged active drug in the urine [55].

 

Conclusion

The need to use thromboprophylaxis after major orthopaedic surgery is now becoming well recognized. However, adequate administration of thromboprophylaxis regimens does not seem to occur after total joint arthroplasty in a large number of cases. The reasons for this appear complex, involving surgeons’ poor awareness of the problem of post-surgical thrombosis, their attitudes to guidelines, concerns about causing bleeding, and the complexities of anticoagulation with current agents. Simplifying therapy, such as once-daily fixed dosing, could change attitudes to anticoagulant use and improve adherence to guidelines. Newly developed, oral, fixed-dose anticoagulants should enable substantial improvement in thromboprophylaxis usage, thereby improving patient outcomes. The primary drawback of the new anticoagulants, particularly those with a long half-life, is the lack of specific antidotes to reverse their anticoagulant effect [56]. Specific antidotes might be needed in particular situations such as for overdose or emergency surgery. However, this may not pertain to dabigatran and rivaroxaban as they have relatively short half-lives (12–14 hours and 7–11 hours, respectively) [45, 53]. As off-label prescribing is not uncommon, there is a risk that new anticoagulants licensed for thromboprophylaxis after THA or TKA will be prescribed for unlicensed indications [57]. These current challenges could be overcome by finding specific antidotes and post-approval surveillance of off-label prescribing.

References

            1.         W. H. Geerts, D. Bergqvist, G. F. Pineo, et al., “Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, vol. 133, no. 6 Suppl, pp. 381S–453S, 2008.

            2.         O. E. Dahl, D. Bergqvist, “Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery,” Current Opinion in Pulmonary Medicine, vol. 8, no. 5, pp. 394–397, 2002.

            3.         H. M. Zaw, I. C. Osborne, P. N. Pettit, and A. T. Cohen, “Risk factors for venous thromboembolism in orthopedic surgery,” The Israel Medical Association Journal, vol. 4, no. 11, pp. 1040–1042, 2002.

            4.         J. A. Caprini, T. M. Hyers, “Compliance with antithrombotic guidelines,” Managed Care, vol. 15, no. 9, pp. 49–66, 2006.

            5.         A. K. Kakkar, B. L. Davidson, and S. K. Haas, “Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines,” Journal of Thrombosis and Haemostasis, vol. 2, no. 2, pp. 221–227, 2004.

            6.         V. F. Tapson, T. M. Hyers, A. L. Waldo, et al., “Antithrombotic therapy practices in US hospitals in an era of practice guidelines,” Archives of Internal Medicine, vol. 165, no. 13, pp. 1458–1464, 2005.

            7.         D. Warwick, O. E. Dahl, and W. D. Fisher, “Orthopaedic thromboprophylaxis: limitations of current guidelines,” The Journal of Bone and Joint Surgery (Proceedings), vol. 90, no. 2, pp. 127–132, 2008.

            8.         Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development, JAMA: The Journal of the American Medical Association, vol. 256, no. 6, pp. 744–749, 1986.

            9.         J. Ansell, J. Hirsh, E. Hylek, et al., “Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition),” Chest, vol. 133, no. 6 Suppl, pp. 160S–198S, 2008.

            10.       J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, et al., “Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety,” Chest, vol. 119, no. 1 Suppl, pp. 64S–94S, 2001.

            11.       Arixtra (fondaparinux sodium)-Prescribing Information, http://us.gsk.com/products/assets/us_arixtra.pdf, 2005.

            12.       G. Agnelli, G. B. Mancini, and D. Biagini, “The rationale for long-term prophylaxis of venous thromboembolism,” Orthopedics, vol. 23, no. 6 Suppl, pp. s643–s646, 2000.

            13.       R. J. Friedman, “Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty,” The Journal of the American Academy of Orthopaedic Surgeons, vol. 15, no. 3, pp. 148–155, 2007.

            14.       A. Planes, N. Vochelle, J. Y. Darmon, M. Fagola, M. Bellaud, and Y. Huet, “Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo,” Lancet, vol. 348, no. 9022, pp. 224–228, 1996.

            15.       E. Rahme, K. Dasgupta, M. Burman, et al., “Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery,” Canadian Medical Association Journal, vol. 178, no. 12, pp. 1545–1554, 2008.

            16.       R. J. Friedman, A. S. Gallus, F. D. Cushner, G. Fitzgerald, and F. A. Anderson, Jr., “Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 87–97, 2008.

            17.       F. A. Anderson, Jr., J. Hirsh, K. White, and R. H. Fitzgerald, Jr., “Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry,” Chest, vol. 124, no. 6 Suppl, pp. 349S–356S, 2003.

            18.       D. Warwick, R. J. Friedman, G. Agnelli, et al., “Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry,” The Journal of Bone and Joint Surgery, vol. 89, no. 6, pp. 799–807, 2007.

            19.       O. E. Dahl, “Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now?,” Haemostasis, vol. 30, no. Suppl 2, pp. 101–105, 2000.

            20.       S. Z. Goldhaber, A. G. Turpie, “Prevention of venous thromboembolism among hospitalized medical patients,” Circulation, vol. 111, no. 1, pp. e1–e3, 2005.

            21.       C. Kearon, “Duration of venous thromboembolism prophylaxis after surgery,” Chest, vol. 124, no. 6 Suppl, pp. 386S–392S, 2003.

            22.       R. H. White, P. S. Romano, H. Zhou, J. Rodrigo, and W. Bargar, “Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty,” Archives of Internal Medicine, vol. 158, no. 14, pp. 1525–1531, 1998.

            23.       S. J. McRae, J. S. Ginsberg, “Initial treatment of venous thromboembolism,” Circulation, vol. 110, no. 9 Suppl 1, pp. I3–I9, 2004.

            24.       P. Prandoni, A. W. Lensing, A. Cogo, et al., “The long-term clinical course of acute deep venous thrombosis,” Annals of Internal Medicine, vol. 125, no. 1, pp. 1–7, 1996.

            25.       C. Kearon, “Natural history of venous thromboembolism,” Circulation, vol. 107, no. 23 Suppl 1, pp. I22–I30, 2003.

            26.       S. R. Kahn, J. S. Ginsberg, “Relationship between deep venous thrombosis and the postthrombotic syndrome,” Archives of Internal Medicine, vol. 164, no. 1, pp. 17–26, 2004.

            27.       V. Pengo, A. W. Lensing, M. H. Prins, et al., “Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2257–2264, 2004.

            28.       J. A. Caprini, M. F. Botteman, J. M. Stephens, et al., “Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States,” Value Health, vol. 6, no. 1, pp. 59–74, 2003.

            29.       K. K. Knight, J. Wong, O. Hauch, G. Wygant, D. Aguilar, and J. J. Ofman, “Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients,” Value Health, vol. 8, no. 3, pp. 191–200, 2005.

            30.       S. D. Sullivan, S. R. Kahn, B. L. Davidson, L. Borris, P. Bossuyt, and G. Raskob, “Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery,” Pharmacoeconomics, vol. 21, no. 7, pp. 477–496, 2003.

            31.       A. Spyropoulos, “Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations,” Journal of Managed Care Pharmacy, vol. 13, no. 6, pp. 475–486, 2007.

            32.       B. Detournay, A. Planes, N. Vochelle, and F. Fagnani, “Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement,” Pharmacoeconomics, vol. 13, no. 1 Pt 1, pp. 81–89, 1998.

            33.       G. Agnelli, M. R. Taliani, and M. Verso, “Building effective prophylaxis of deep vein thrombosis in the outpatient setting,” Blood Coagulation and Fibrinolysis, vol. 10 Suppl 2, pp. S29–S35, 1999.

            34.       B. I. Eriksson, D. J. Quinlan, “Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery,” Drugs, vol. 66, no. 11, pp. 1411–1429, 2006.

            35.       J. I. Weitz, “Emerging anticoagulants for the treatment of venous thromboembolism,” Thrombosis and Haemostasis, vol. 96, no. 3, pp. 274–284, 2006.

            36.       M. C. Sokol, K. A. McGuigan, R. R. Verbrugge, and R. S. Epstein, “Impact of medication adherence on hospitalization risk and healthcare cost,” Medical Care, vol. 43, no. 6, pp. 521–530, 2005.

            37.       A. Gillissen, “Patients adherence in asthma,” Journal of Physiology and Pharmacology, vol. 58, no. Suppl 5, pp. 205–222, 2007.

            38.       B. V. Patel, R. S. Leslie, P. Thiebaud, et al., “Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen,” Vascular Health and Risk Management, vol. 4, no. 3, pp. 673–681, 2008.

            39.       B. A. Boyle, D. Jayaweera, M. D. Witt, K. Grimm, J. F. Maa, and D. W. Seekins, “Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression,” HIV Clinical Trials, vol. 9, no. 3, pp. 164–176, 2008.

            40.       J. Ansell, “Factor Xa or thrombin: is factor Xa a better target?,” Journal of Thrombosis and Haemostasis, vol. 5 Suppl. 1, pp. 60–64, 2007.

            41.       B. I. Eriksson, O. E. Dahl, N. Rosencher, et al., “Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007.

            42.       J. S. Ginsberg, B. L. Davidson, P. C. Comp, et al., “Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery,” Journal of Arthroplasty, vol. 24, no. 1, pp. 1–9, 2009.

            43.       B. I. Eriksson, O. E. Dahl, N. Rosencher, et al., “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial,” Lancet, vol. 370, no. 9591, pp. 949–956, 2007.

            44.       B. I. Eriksson, R. Friedman, “Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty,” Clinical and Applied Thrombosis/Hemostasis, vol. 15, pp. 25S–31S, 2009.

            45.       Dabigatran Summary of Product Characteristics, “Pradaxa® (dabigatran etexilate) Summary of Product Characteristics,” http://www.pradaxa.com/Include/media/pdf/Pradaxa_SPC_EMEA.pdf, 2008.

            46.       K. A. Bauer, “New anticoagulants,” Current Opinion in Hematology, vol. 15, no. 5, pp. 509–515, 2008.

            47.       B. I. Eriksson, L. C. Borris, O. E. Dahl, et al., “A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement,” Circulation, vol. 114, pp. 2374–2381, 2006.

            48.       W. Mueck, B. I. Eriksson, K. A. Bauer, et al., “Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor xa inhibitor – in patients undergoing major orthopaedic surgery,” Clinical Pharmacokinetics, vol. 47, no. 3, pp. 203–216, 2008.

            49.       B. I. Eriksson, L. C. Borris, R. J. Friedman, et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2765–2775, 2008.

            50.       A. K. Kakkar, B. Brenner, O. E. Dahl, et al., “Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial,” Lancet, vol. 372, pp. 31–39, 2008.

            51.       M. R. Lassen, W. Ageno, L. C. Borris, et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2776–2786, 2008.

            52.       A. G. G. Turpie, M. R. Lassen, B. L. Davidson, et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial,” Lancet, vol. 373, no. 9676, pp. 1673–1680, 2009.

            53.       Xarelto® Summary of Product Characteristics, http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf, 2009.

            54.       S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth, “The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans,” Drug Metabolism and Disposition, vol. 36, no. 2, pp. 386–399, 2008.

            55.       C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang, “Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans,” Drug Metabolism and Disposition, vol. 37, no. 5, pp. 1056–1064, 2009.

            56.       J. I. Weitz, J. Hirsh, and M. M. Samama, “New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, vol. 133, no. 6 Suppl, pp. 234S–256S, 2008.

            57.       D. C. Radley, S. N. Finkelstein, and R. S. Stafford, “Off-label prescribing among office-based physicians,” Archives of Internal Medicine, vol. 166, no. 9, pp. 1021–1026, 2006.

Dr. Friedman is a Clinical Professor of Orthopaedic Surgery at The Medical University of South Carolina and Chairman of the Department of Orthopaedic Surgery of Roper Hospital, Charleston, SC, USA.  He is a world reknown leader in the prevention of deep vein thrombosis.

True Success

January 25th, 2011

by Tom Morris

From Plato and Aristotle to the present day, the wisest people who have ever thought about challenge and achievement in our lives and work have left us bits and pieces of powerful advice for attaining true success in anything we do. I’ve put these ideas together in a simple framework of seven universal conditions. Let me lay them out briefly and then we’ll look at each. Whether you apply them in your practice, in your life, or teach them to your patients, they can be very helpful for focusing on what it takes to reach important goals.

The 7 Cs of Success

For the most deeply satisfying and sustainable forms of success, we need to bring into any challenge, opportunity, or relationship:

(1) A clear CONCEPTION of what we want, a vivid vision, a goal clearly imagined.

(2) A strong CONFIDENCE that we can attain that goal.

(3) A focused CONCENTRATION on what it takes to reach the goal.

(4) A stubborn CONSISTENCY in pursuing our vision.

(5) An emotional COMMITMENT to the importance of what we’re doing.

(6) A good CHARACTER to guide us and keep us on a proper course.

(7) A CAPACITY TO ENJOY the process along the way.

There are certainly other concepts often associated with success, but every other one is just a version or application of one of these in specific situations. The 7 Cs give us the most universal, logical, and comprehensive framework for success.

(1) A clear CONCEPTION of what we want, a vivid vision, a goal clearly imagined.

In any facet of our lives, we need to think through as clearly as possible what we want to accomplish. True success starts with an inner vision, however incomplete it might be. The world as we find it is just the raw material for what we can make it. We are meant to be artists with our energies and our lives. And the only way to do that well is to structure our actions around clear goals.

(2) A strong CONFIDENCE that we can attain the goal.

Inner attitude is a key to outer results. Philosopher William James learned from championship athletes that a proper confidence should be operative in all our lives. In any new enterprise, we need upfront faith in what we’re doing. Sometimes we may have to work hard to generate this attitude. But it’s worth the work it takes, because it raises our prospects for success. The best confidence arises out of competence and then augments it.  It’s of course no guarantee of success. But it is among the chief contributors to it.

(3) A focused CONCENTRATION on what it takes to reach the goal.

Big dreams just lead to big disappointments when people don’t learn how to chart their way forward. Success at anything challenging comes from planning your path and then putting that plan into action. Gestalt psychologists teach us that a new mental focus generates new perceptual abilities. Concentrating your thought and energy in a new direction, toward a clear goal, you begin to see things that you might have missed before, that relate to the goal you’ve set. This focus allows you to plan and act, and adjust along the way. Even a flawed plan can start you off and lead you to where you can discover a better one. A focused concentration of thought and action is key.

(4) A stubborn CONSISTENCY in pursuing our vision.

The word ‘consistency’ comes from two Greek roots, a verb meaning “to stand” and a particle meaning “together.” Consistency is all about standing together. Do my actions stand together with my words? Do my reactions and emotions stand together with my deepest beliefs and values? Do the people I work with stand together? This is what consistency is all about. It’s a matter of unifying your energy and efforts in a single direction. Inconsistency defuses power. Consistency moves us toward our goals.

(5) An emotional COMMITMENT to the importance of what we’re doing.

Passion is the core of extraordinary success. It’s a key to overcoming difficulties, seizing opportunities, and getting other people excited about your projects. Too much goal setting in the modern world has been an exercise of the intellect and not also of the heart. Philosophers appreciate the role of rationality in human life. But we know that it’s not just the head, but also the heart, that can guide us on to the tasks right for us, and keep us functioning at the peak of our abilities.

(6) A good CHARACTER to guide us and keep us on a proper course.

Character inspires trust. And trust is necessary for people to work together well. Good character is required for great collaboration. In a world in which innovative partnerships and collaborative synergies are increasingly important, the moral foundation for working well together matters more than ever before. And good character does a lot more than just provide for trust. It has an effect on each individual’s own freedom and insight. Bad character not only corrupts, it blinds. A person whose perspective has been deeply skewed by selfishness or mendacity cannot understand the world in as perceptive a way as someone whose sensibilities are ethically well formed. Good character makes sustainable success more likely.

(7) A CAPACITY TO ENJOY the process along the way.

The more you can enjoy the process of what you’re doing, the better the results tend to be. It’s easier to set creative goals. Confidence will come more naturally. Your concentration can seem effortless. Consistency will not be a battle. The emotional commitment will flow. And issues of character will not be as difficult to manage. A capacity to enjoy the process is entwined with every other facilitator of success in a great many ways.

****

These conditions of success are all deeply connected. They constitute a unified framework of tools with which we can work our way toward the most fulfilling forms of achievement. They will help us to make our proper mark in the world. They will move us in the direction of true success. And why should we ever settle for anything less?

 Tom Morris is the author of such books as True Success, The Art of Achievement, If Aristotle Ran General Motors, and If Harry Potter Ran General Electric. He writes weekly for The Huffington Post and can be found philosophizing on Twitter as TomVMorris.  He can be reached at TomVMorris@aol.com or through the Morris Institute.

Dr. Morris was kind enough to guest author this article for OrthopaedicLIST.com.

The Quest for Flexible Fixation with Locking Plates

January 4th, 2011

By Michael Bottlang, PhD

A 2004 editorial entitled ‘‘When Evolution Begets Revolution’’ described locking plates as the next great advance in orthopaedic traumatology that was adopted at an unprecedented speed [1]. The editorial concluded with the prudent prediction that ‘‘this wave of enthusiasm will surely be followed with an analysis of the inherent problems, followed by a truer understanding of the role of these implants.” Today, locking plates are recognized for the superior fixation strength of fixed-angle locking screws, particularly for metaphyseal fixation in osteoporotic bone. They furthermore support biological fixation, allowing subcutaneous plating while preserving periosteal perfusion. Hence, they satisfy two out of three principal aspects of fracture fixation, being stable fixation, preservation of biology, and promotion of fracture healing.

 The latter aspect of fracture healing is increasingly being recognized as an inherent problem of the current generation of locking plates. If locking plates do not provide a mechanical environment that promotes fracture healing, they become prone to losing the race between healing and fixation failure, leading to late implant breakage and loss of fixation. There is growing evidence from clinical and animal studies that the inherent stiffness of a locked plating construct can suppresses fracture motion to a level that is insufficient to promote fracture healing by callus formation [2-4].

With hindsight, locked bridge plating constructs pose an apparent conundrum: They provide inherently rigid stabilization, yet they should facilitate secondary bone healing that relies on flexible fixation to stimulate callus formation. To resolve this conundrum, we developed a modified locked plating concept, termed Far Cortical Locking (FCL) that enables flexible fixation with locking plates [4,5]. FCL reduces the stiffness of a locked plating construct by means of FCL screws that are fixed in the plate and in the far cortex while retaining a controlled motion envelope in the near cortex of a diaphysis. FCL screws have a flexible shaft with a reduced diameter that can elastically deflect within the near cortex motion envelope. The motion envelope is controlled by the diameter of a collar segment adjacent to the FCL screw head. FCL constructs therefore resemble a monolateral external fixator, the bar of which has been applied close to the bone surface and the pins of which are secured in the far cortex rather than in the near cortex.

A biomechanical study has shown that FCL screws reduce the stiffness of locked plating construct by over 80% while retaining comparable strength [5]. An in vivo study has furthermore shown that FCL constructs reliably yielded bridging of all cortices, causing healed fractures to be 156% stronger than control fractures stabilized with standard locked plating constructs [4]. Most interestingly, standard locked constructs suppressed fracture healing at the cortex under the plate where fracture motion is minimal. A clinical study is currently being conducted to document the effect of FCL screws on healing of supracondylar femur fractures.

The facts that controlled interfragmentary motion can promote fracture healing while absence of motion will suppress callus formation have long been recognized in the external fixator literature, particularly by the landmark studies of Goodship and Kenwright [6] and Claes [7]. As such, the evolution of locked plating towards more flexible fixation is both novel and conservative. If clinical results should support the prior finding on improved healing with FCL, they will likely inspire a variety of implant solutions aimed at providing flexible fixation with locking plates. These solutions will be key for the quest on flexible fixation with locking plates. However, solutions should be supported by evidence on their ability to promote fracture healing while ensuring that flexible fixation is not gained on cost of fixation strength. Such next generation of flexible locking plates will resemble true internal fixators that replicate the biomechanical behavior of external fixators by allowing adequate interfragmentary motion to promote the natural fracture healing cascade via callus formation. It is the hope of the author that this evolution will in turn resolve the misnomer “secondary” bone healing by recognizing the prime importance of this natural healing cascade for the vast majority of fractures.

Dr. Bottlang is the Director of the Legacy Biomechanics Laboratory in Portland, OR, USA. His research is focused on orthopaedic trauma and fracture care. His line of research on FCL was funded by the NIH and has received the Award of Excellence at the 2010 meeting of the American Association of Orthopaedic Surgeons. He holds several patents and has contributed to the development of several devices, including Zimmer “MotionLoc” FCL screws for which he receives royalties.

Note:  Listings of the MotionLoc FCL screws and the NCB Polyaxial Plate can be found on OrthopaedicLIST.com.

[1] Sanders R. When evolution begets revolution. J Orthop Trauma. 2004;18:481-482.

[2] Henderson CE, Bottlang M, Marsh JL, Fitzpatrick DC, Madey SM. Does locked plating of periprosthetic supracondylar femur fractures promote bone healing by callus formation? Iowa Orthop J. 2008;28:73-6.

[3] Lujan TJ, Henderson CE, Madey SM, Fitzpatrick DC, Marsh JL, Bottlang M. Locked plating of distal femur fractures leads to inconsistent and asymmetric callus formation. J Orthop Trauma. 2010;24-3:156-62.

[4]  Bottlang M, Lesser M, Koerber J, Doornink J, von Rechenberg B, Augat P, Fitzpatrick DC, Madey SM, Marsh JL. Far cortical locking can improve healing of fractures stabilized with locking plates. The Journal of bone and joint surgery. 2010;92:1652-1660.

[5] Bottlang M, Doornink J, Fitzpatrick DC, Madey SM. Far Cortical Locking can reduce the stiffness of locked plating constructs while retaining construct strength. J Bone and Joint Surg. 2009; 91(8):1985-1994.

[6] Goodship AE, Kenwright J. The influence of induced micromovement upon the healing of experimental tibial fractures. J Bone Joint Surg Br. 1985;67-4:650-5.

[7] Claes LE, Wilke HJ, Augat P, Rubenacker S, Margevicius KJ. Effect of dynamization on gap healing of diaphyseal fractures under external fixation. Clin Biomech (Bristol, Avon) 1995;10-5:227-34.